Unaffected men >40 years found to carry a BRCA2 mutation are recommended to have annual PSA-based prostate cancer screening.24 Recommendations for male carriers of germline mutations in non-BRCA genes are less clear. This evidence concerns the gene BRCA2 and prostate cancer.